These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33911178)

  • 1. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
    Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
    Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two effects of GATA2 enhancer repositioning by 3q chromosomal rearrangements.
    Suzuki M; Katayama S; Yamamoto M
    IUBMB Life; 2020 Jan; 72(1):159-169. PubMed ID: 31820561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
    Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
    Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.
    Yamazaki H; Suzuki M; Otsuki A; Shimizu R; Bresnick EH; Engel JD; Yamamoto M
    Cancer Cell; 2014 Apr; 25(4):415-27. PubMed ID: 24703906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chromosomal rearrangements between 3q21 and 3q26 induce leukemogenesis by misdirecting both EVI1 and GATA2 genes].
    Suzuki M
    Rinsho Ketsueki; 2017; 58(7):806-812. PubMed ID: 28781278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
    Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
    Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
    Gröschel S; Sanders MA; Hoogenboezem R; de Wit E; Bouwman BAM; Erpelinck C; van der Velden VHJ; Havermans M; Avellino R; van Lom K; Rombouts EJ; van Duin M; Döhner K; Beverloo HB; Bradner JE; Döhner H; Löwenberg B; Valk PJM; Bindels EMJ; de Laat W; Delwel R
    Cell; 2014 Apr; 157(2):369-381. PubMed ID: 24703711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.
    Yamaoka A; Suzuki M; Katayama S; Orihara D; Engel JD; Yamamoto M
    Blood Adv; 2020 Apr; 4(8):1722-1736. PubMed ID: 32330245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
    Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
    Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
    Cooper S; Guo H; Friedman AD
    PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.
    Smeenk L; Ottema S; Mulet-Lazaro R; Ebert A; Havermans M; Varea AA; Fellner M; Pastoors D; van Herk S; Erpelinck-Verschueren C; Grob T; Hoogenboezem RM; Kavelaars FG; Matson DR; Bresnick EH; Bindels EM; Kentsis A; Zuber J; Delwel R
    Cancer Discov; 2021 Nov; 11(11):2868-2883. PubMed ID: 33980539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.
    Loke J; Assi SA; Imperato MR; Ptasinska A; Cauchy P; Grabovska Y; Soria NM; Raghavan M; Delwel HR; Cockerill PN; Heidenreich O; Bonifer C
    Cell Rep; 2017 May; 19(8):1654-1668. PubMed ID: 28538183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
    Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
    Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia.
    Simeoni F; Romero-Camarero I; Camera F; Amaral FMR; Sinclair OJ; Papachristou EK; Spencer GJ; Lie-A-Ling M; Lacaud G; Wiseman DH; Carroll JS; Somervaille TCP
    Cell Rep; 2021 Sep; 36(12):109725. PubMed ID: 34551306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
    Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
    Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function.
    Tokita K; Maki K; Mitani K
    Cancer Sci; 2007 Nov; 98(11):1752-7. PubMed ID: 17894555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.
    Cheng CK; Chan NP; Wan TS; Lam LY; Cheung CH; Wong TH; Ip RK; Wong RS; Ng MH
    Haematologica; 2016 Apr; 101(4):448-57. PubMed ID: 26802049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.
    Marchesini M; Gherli A; Simoncini E; Tor LMD; Montanaro A; Thongon N; Vento F; Liverani C; Cerretani E; D'Antuono A; Pagliaro L; Zamponi R; Spadazzi C; Follini E; Cambò B; Giaimo M; Falco A; Sammarelli G; Todaro G; Bonomini S; Adami V; Piazza S; Corbo C; Lorusso B; Mezzasoma F; Lagrasta CAM; Martelli MP; La Starza R; Cuneo A; Aversa F; Mecucci C; Quaini F; Colla S; Roti G
    Nat Commun; 2024 Jun; 15(1):4739. PubMed ID: 38834613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
    Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
    Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.